StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
ROSSARI.NS$522.15-3.42%
Fair $522.15+0.0%

ROSSARI.NS

Rossari Biotech Limited

Basic Materials / Specialty ChemicalsNSE

$522.15

-18.35 (-3.42%)

Fairly Valued+0.0%Fair Value $522.15Fund rank 24/100 · Data gapFallback financials|
SA 48/C
F-Score: 2/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 17%

FCF escenarios

weak_data · normalized FCF $-880.3M · quality 39.7/100

Data gap 24/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 10/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

48/100

C

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists.
Thesis & Journal · ROSSARI.NSLocal privado en este navegador · Rossari Biotech Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$28.9B

P/E

19.4x

↑

EV/EBITDA

10.5x

↓

ROE

11.2%

↑

Gross Margin

30.4%

↑

Debt/Equity

0.33

↑
52-Week Range$522
$375$766

TradingView lightweight chart

ROSSARI.NS price, volumen y niveles de valoración

Último $518.85Periodo -30.0%
Fair value: $522.15

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2023–2026 · 3 años de histórico normalizado

Revenue CAGR

+13.2%

FCF CAGR

—

FCF margin

-8.3%

FCF / Net income

-1.34x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $23.96B · net income $1.49B · FCF $-2.00B

2023-FY → 2026-FY

Gross margin

30.4%+1.7% pts

Operating margin

8.6%-0.6% pts

Net margin

6.2%-0.3% pts

FCF margin

-8.3%-15.5% pts
MetricTTM
2026
2025
2024
2023
Income Statement
Revenue$23.96B$23.96B$20.80B$18.25B$16.51B
Net Income$1.49B$1.49B$1.36B$1.31B$1.07B
EBITDA$3.10B$3.10B$2.70B$2.57B$2.29B
EPS——24.6323.6219.38
Gross Margin30.4%30.4%31.1%28.6%28.6%
Operating Margin8.6%8.6%9.5%10.0%9.2%
Net Margin6.2%6.2%6.6%7.2%6.5%
Balance Sheet
Debt/Equity0.330.330.180.110.08
Current Ratio1.561.56———
Cash Flow
Free Cash Flow$-2.00B$-2.00B$-210.7M$-880.3M$1.19B
Returns
ROE11.2%11.2%11.5%12.5%11.7%
Valuation
P/E19.3919.3925.2130.4132.29
EV/EBITDA10.4910.4913.3715.8015.12
P/B2.172.172.903.793.79
Growth & Yield
Revenue Growth15.2%15.2%14.0%10.5%—
EPS Growth——4.3%21.9%—
Dividend Yield0.1%0.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -21.3%

Total return

-21.3%

Start / end P/E

n/dx → n/dx

EPS bridge

24.63 → n/d

Residual

-21.4%

EPS growthn/d
Multiple reratingn/d
Dividend+0.1%
Residual / FX / buybacks / cross-term-21.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.